.Johnson & Johnson’s deprioritization of its own contagious illness pipe has claimed one more sufferer in the form of its dengue infection vaccine mosnodenvir.Mosnodenvir is actually developed to block out interactions between 2 dengue virus healthy proteins. The injection made it through J&J’s choice in 2015 to combine its transmittable health condition and also injection operations, which observed the likes of a late-stage respiratory syncytial virus program lost from the Big Pharma’s pipeline and an E. coli injection liquidated to Sanofi.Mosnodenvir has actually had a tough time in the center, along with J&J terminating one litigation due to the impact of COVID-19 on enrollment and also stopping briefly recruitment in yet another research in 2022.
Yet the devotion to mosnodenvir appeared to pay off in October 2023, when the injection was actually presented to cause a dose-dependent antiviral effect on the detectability and beginning of dengue virus serotype 3 in a phase 2 trial. That information drop does not appear to have actually sufficed to save mosnodenvir for long, with the Big Pharma introducing this morning that it is ceasing a follow-up phase 2 field study. The decision is actually related to a “critical reprioritization of the provider’s pandemic diseases R&D collection,” added J&J, which stressed that no safety and security issues had been actually determined.” Johnson & Johnson will certainly remain to assist the fight against dengue by sharing research leads along with the clinical community in the future,” the pharma claimed in the launch.J&J had been investing in dengue for over a years, consisting of launching a Satellite Center for Global Health Discovery at the Duke-NUS Medical School in Singapore in 2022.
The center has actually been actually concentrated on accelerating early-stage exploration research study to “take care of the increasing problem of flaviviruses” such as dengue and also Zika.